These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 22772485)

  • 1. Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis.
    Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Bartlett K; Wasan KM
    Int J Pharm; 2012 Oct; 436(1-2):318-23. PubMed ID: 22772485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
    Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
    Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis.
    Ibrahim F; Sivak O; Wasan EK; Bartlett K; Wasan KM
    Lipids Health Dis; 2013 Oct; 12():158. PubMed ID: 24164705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice.
    Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
    Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
    J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.
    Petraitiene R; Petraitis V; Kelaher AM; Sarafandi AA; Mickiene D; Groll AH; Sein T; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 2005 May; 49(5):2084-92. PubMed ID: 15855534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.
    Gershkovich P; Wasan EK; Lin M; Sivak O; Leon CG; Clement JG; Wasan KM
    J Antimicrob Chemother; 2009 Jul; 64(1):101-8. PubMed ID: 19398459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).
    Gershkovich P; Sivak O; Wasan EK; Magil AB; Owen D; Clement JG; Wasan KM
    J Antimicrob Chemother; 2010 Dec; 65(12):2610-3. PubMed ID: 20861140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
    Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
    Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats.
    Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Wasan KM
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1277-83. PubMed ID: 22989082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
    Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
    Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model.
    Sivak O; Gershkovich P; Lin M; Wasan EK; Zhao J; Owen D; Clement JG; Wasan KM
    Lipids Health Dis; 2011 Aug; 10():135. PubMed ID: 21824435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
    Zhang Z; Diener RM; Lipman JM
    Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans.
    Wasan EK; Bartlett K; Gershkovich P; Sivak O; Banno B; Wong Z; Gagnon J; Gates B; Leon CG; Wasan KM
    Int J Pharm; 2009 May; 372(1-2):76-84. PubMed ID: 19236839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
    Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
    Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis.
    Garcia A; Adler-Moore JP; Proffitt RT
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2327-32. PubMed ID: 10952575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amphotericin-B-loaded polymersomes formulation (PAMBO) based on (PEG)₃-PLA copolymers: an in vivo evaluation in a murine model.
    Jain JP; Jatana M; Chakrabarti A; Kumar N
    Mol Pharm; 2011 Feb; 8(1):204-12. PubMed ID: 21138276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-infectious effect of sustained antravitreal amphotericin B drug delivery system on experimental rabbit fungal endophthalmitis of Candida albicans].
    Chen N; Yang YT; Dong XG; Xie LX; Wang SG
    Zhonghua Yan Ke Za Zhi; 2006 May; 42(5):420-5. PubMed ID: 16762236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection.
    Alsaadi M; Italia JL; Mullen AB; Ravi Kumar MN; Candlish AA; Williams RA; Shaw CD; Al Gawhari F; Coombs GH; Wiese M; Thomson AH; Puig-Sellart M; Wallace J; Sharp A; Wheeler L; Warn P; Carter KC
    J Control Release; 2012 Jun; 160(3):685-91. PubMed ID: 22516093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.